Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep760 | Thyroid | ECE2021

Graves’ Disease after COVID-19

Moreno Tirado Antonio , Paloma González Lázaro , Contreras Pascual Cristina , Montalban Mendez Cristina , Maria Zhao Montero Benítez , Florentino Del Val Zaballos

IntroductionGraves’ Disease is an autoimmune syndrome that include hyperthyroidism, goiter, thyroid eye disease, and occasionally, a dermopathy called pretibial or localized myxedema. As each autoinmune ailment to develop in sufferers with genetic susceptibility after a certain environmental exposure (infection, stress…). COVID-19 can cause both pulmonary and systemic inflammation, potentially determining multi-organ dysfunction. Since the out...

ea0073aep454 | General Endocrinology | ECE2021

Acute pancreatitis in a covid-19 patient

Maria Zhao Montero Benítez , Pascual Cristina Contreras , Mendez Cristina Montalban , Tirado Antonio Moreno , Paloma González Lázaro , Florentino Del Val Zaballos , Julia Silva-Fernández , Meneses Amparo Lomas , Francisco Javier Gómez Alfonso , Inés Gómez García

Acute pancreatitis (AP) is an inflammatory disorder of the pancreas, most commonly caused by gallstones and heavy alcohol consumption. The diagnosis is established with at least 2 of the following criteria: abdominal pain; increased serum lipase/amylase levels greater than 3 times the upper limit of normal value; or characteristic findings on contrast computed tomography (CT). Since the beginning of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic, a few...

ea0073ep202 | Thyroid | ECE2021

Selpercatinib as an alternative therapy to Lenvatinib for metastatic medullary thyroid cancer. A case report.

Contreras Pascual Cristina , Montalban Mendez Cristina , Moreno Tirado Antonio , Maria Zhao Montero Benítez , Paloma González Lázaro , Julia Silva-Fernández , Florentino Del Val Zaballos , Francisco Javier Gómez Alfonso , Lomas Meneses Amparo , Inés Gómez García

Selpercatinib is a receptor tyrosine kinase RET inhibitor for the treatment of cancers such as RET-mutant medullary thyroid cancer, demonstrating partial response and low incidence of serious adverse events. Vandetanib, a tyrosine kinase inhibitor, has shown promising results with an increase in progression-free survival and prolonged lifetime, but it causes adverse events such as hypertension, diarrhea, rash, or long QT interval. Most of them are can be even disabling for the...